<DOC>
	<DOCNO>NCT01169584</DOCNO>
	<brief_summary>This Phase I , open-label , dose-escalation trial JX-594 ( Pexa-Vec ) pediatric patient advanced/metastatic , unresectable solid tumor refractory standard therapy and/or patient tolerate standard therapy . Tumors likely include neuroblastoma , lymphoma , Wilms ' tumor , rhabdomyosarcoma , Ewing 's sarcoma , osteosarcoma , non-rhabdomyosarcoma soft tissue sarcoma , malignant peripheral nerve sheath tumor . Benign tumor exclude . These tumor type select evidence biological activity observe cancer cell line ex vivo infect primary human tissue sample , specifically pediatric cancer type sarcomas neuroblastoma .</brief_summary>
	<brief_title>Safety Study Recombinant Vaccinia Virus Treat Refractory Solid Tumors Pediatric Patients</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<criteria>Age 2 21 year Histologicallyconfirmed , advanced/metastatic nonCNS solid tumor relapse and/or refractory standard therapy ( progressive disease despite therapy ) and/or patient tolerate standard therapy . NonCNS solid tumor eligible likely include histology neuroblastoma , Wilms ' tumor , rhabdomyosarcoma , Ewing 's sarcoma , osteosarcoma , nonrhabdomyosarcoma soft tissue sarcoma , malignant peripheral nerve sheath tumor . Cancer surgically resectable cure At least one measurable tumor mass CT/MRI ( i.e . lesion accurately measure least one dimension long diameter ≥ 1 cm ) inject direct visualization/palpitation imagingguidance ( CT ultrasound ) Expected survival approximately 8 week longer Lansky Score ≥ 50 Total bilirubin ≤ 2.5 × ULN AST , ALT ≤ 2.5 × ULN ( liver tumor ( ) present : AST/ALT ≤ 5 x ULN ) Serum creatinine ≤ 1.8 x ULN INR ≤ 1.5 x ULN Hematologic parameter : Patients transfuse meet entry criterion . Hemoglobin ≥ 9 g/dL For bone marrow negative patient : ANC ≥ 750 cells/ mm3 platelet count ≥ 75,000 plts/mm3 For bone marrow positive patient : ANC ≥ 750 cells/ mm3 . Platelet count recovery requirement , platelet transfuse ≥ 75,000 plts/ mm3 prior treatment . CD4 count ≥ 200/mm3 . Patients demonstrate intact delayedtype hypersensitivity ( DTH ) via skin immune response common antigen ( e.g . candida , mumps ) also eligible . For patient sexually active , able willing abstain sexual activity 3 week follow treatment JX594 . Thereafter , able willing use accept birth control method 3 month last treatment JX594 . [ Acceptable birth control method include contraceptive pill , condom , IUD , diaphragm sponge + spermicide , method &gt; 97 % effectiveness ] Able willing sign Institutional Review Board ( IRB ) /Research Ethics Board ( REB ) approve write consent form ( patient and/ parents/guardians ) . Able willing comply study procedure followup examination , include compliance `` Infection Control Guidelines Patients '' contain within write consent form ( patient and/ parents/guardians ) . Pregnant nursing infant Injected tumor ( ) location would potentially result significant clinical adverse effect posttreatment tumor swell occur deem unsafe investigator ( e.g . tumor impinge upper airway affect biliary tract drainage , adherent and/or invade major vascular structure , CNS , etc . ) Brain metastasis , unless surgically resect and/or irradiate . ( Brain metastasis consider site injection ) . Patients lymphomas Use high dose systemic corticosteroid immune suppressive medication within 3 week first treatment ( e.g . cortisone , dexamethasone , hydrocortisone , prednisone , prednisolone , interferon , cisplatin , doxorubicin , fluorouracil , etc. ) . * Note : patient take lowdose corticosteroid treatment nausea and/or take maintenance corticosteroid adrenal insufficiency permit enroll . Known infection HIV know underlying genetic immunodeficiency disease Treatment inject tumor ( ) radiotherapy , chemotherapy , surgery , investigational drug within 3 week prior first treatment Clinically significant active infection uncontrolled medical condition consider high risk investigational new drug treatment ( e.g . pulmonary , neurological , cardiovascular , gastrointestinal , genitourinary ) History exfoliative skin condition ( e.g . severe eczema , ectopic dermatitis , similar skin disorder ) require systemic therapy Clinically significant and/or rapidly accumulate ascites , pericardial and/or pleural effusion ( e.g . require drainage symptom control ) Severe unstable cardiac disease may include , limited , follow within 6 month prior screen : myocardial infarct , unstable angina , congestive heart failure , myocarditis , arrhythmia diagnose require medication , clinicallysignificant change cardiac status Current , active , progress CNS malignancy , include carcinomatosis meningitis ( definitively surgically resect irradiated metastasis allow ) Pulse oximetry O2 saturation &lt; 90 % rest Use antiviral , antiplatelet anticoagulation medication ( example , heparin , warfarin , aspirin , ticlopidine , clopidogrel , dipyridamole ) [ Patients discontinue medication within 7 day prior first treatment may eligible study . Any required , chronic medication indicate medical issue discontinue order meet eligibility criteria trial without consultation patient treat physician . ] Note : Low Dose Heparin maintain patency venous catheter permit . Patients benign tumor Inability unwillingness give inform consent ( patient parent/guardian ) comply procedure require protocol Vaccination live virus ( i.e . measles , mumps , rubella , etc ) &lt; 30 day prior first treatment Patients household contact meet criterion exclude unless alternate living arrangement make patient 's active dosing period three week follow last dose study medication : Women pregnant nursing infant Children &lt; 1 year old People skin disease ( eczema , atopic dermatitis related disease ) Immunocompromised host ( severe deficiency cellmediated immunity , include AIDS , organ transplant recipient , hematologic malignancy )</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Phase I</keyword>
	<keyword>advanced metastatic pediatric solid tumor</keyword>
	<keyword>pediatric</keyword>
	<keyword>vaccinia virus</keyword>
	<keyword>oncolytic virus</keyword>
	<keyword>neuroblastoma</keyword>
	<keyword>rhabdomyosarcoma</keyword>
	<keyword>lymphoma</keyword>
	<keyword>Wilm 's tumor</keyword>
	<keyword>Ewing 's sarcoma</keyword>
	<keyword>osteosarcoma</keyword>
	<keyword>non-rhabdomyosarcoma soft tissue sarcoma</keyword>
	<keyword>malignant peripheral nerve sheath tumor</keyword>
	<keyword>Pexa-Vec</keyword>
</DOC>